{"id":9642,"date":"2026-03-27T11:29:59","date_gmt":"2026-03-27T10:29:59","guid":{"rendered":"https:\/\/www.igmm.cnrs.fr\/abivax-secures-a-record-750-million-to-advance-its-innovative-treatment\/"},"modified":"2026-03-27T11:46:35","modified_gmt":"2026-03-27T10:46:35","slug":"abivax-secures-a-record-750-million-to-advance-its-innovative-treatment","status":"publish","type":"post","link":"https:\/\/www.igmm.cnrs.fr\/en\/abivax-secures-a-record-750-million-to-advance-its-innovative-treatment\/","title":{"rendered":"Abivax secures a record $750 million to advance its innovative treatment"},"content":{"rendered":"

\"\"<\/p>\n

The biotech company Abivax<\/a> has raised $750 million to develop obefazimod, an oral treatment for ulcerative colitis.
\nThis molecule is the result of over 20 years of research led by Prof. Jamal Tazi at the Institut de G\u00e9n\u00e9tique mol\u00e9culaire de Montpellier (IGMM).
\nThis innovative oral treatment showed a significant clinical remission rate and a good safety profile in phase III trials, with commercialization expected as early as 2027.<\/p>\n

Source: CNRS Innovation<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Record $750M funding for Abivax and its innovative treatment Obefazimod, developed from the research of Prof. Jamal Tazi at IGMM<\/p>\n","protected":false},"author":4,"featured_media":9635,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-9642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-news"],"_links":{"self":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts\/9642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/comments?post=9642"}],"version-history":[{"count":2,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts\/9642\/revisions"}],"predecessor-version":[{"id":9644,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts\/9642\/revisions\/9644"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/media\/9635"}],"wp:attachment":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/media?parent=9642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/categories?post=9642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/tags?post=9642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}